drugset / Trial / NCT04051502

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

NCT04051502

Phase 0 Completed 48 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedSequentialOpen-labelDiagnostic

Summary

The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.

Timeline

Start
2019-08-05
Primary completion
2025-12-08
Completion
2025-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 1 ml Other
Subject Indocyanine Green Diagnostic / imaging agent 2 ml Other
Subject Indocyanine Green Diagnostic / imaging agent 4 ml Other

Indications